Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
暂无分享,去创建一个
A. Quattrone | P. Valentino | C. Torti | T. Tallarico | V. Pisani | S. Barone | S. Scannapieco | G. Demonte | E. Filippelli | D. Console | A. Granata | S. Polidoro
[1] W. Brownlee,et al. Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome , 2017, Multiple sclerosis.
[2] L. Durelli,et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab , 2017, Multiple sclerosis.
[3] H. Hartung,et al. Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.
[4] M. Minemura,et al. Liver involvement in systemic infection. , 2014, World journal of hepatology.
[5] M. Keating,et al. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.
[6] R. Kurzrock,et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders , 2003, Cancer.
[7] R. Mercier,et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J K Greenson,et al. Mini‐microabscess syndrome in liver transplant recipients , 1997, Hepatology.
[9] J. Hamilton,et al. Cytomegalovirus infection following liver transplantation: review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] E. Urbán,et al. Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study , 2016, Annals of Hematology.
[11] N. Kaplowitz,et al. Drug-Induced Liver Injury , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.